Tamoxifen 2% (20mg/mL) Gel, 30mL

Tamoxifen is a Selective Estrogen-Receptor Modifier (SERM), which has both estrogenic AND anti-estrogenic effects on various tissues in the body. It is chemically related to another antiestrogen, clomiphene (see Clomiphene Citrate). 

Gynecomastia is a benign fibrotic proliferation of male breast glandular tissue and can occur in all stages of life. Gynecomastia may be painful and psychologically disturbing in some patients. Gynecomastia may occur as a result of increases in estrogen or decreases in androgen levels. Hormonal shifts causing gynecomastia may occur during puberty and aging but may also be idiopathic or result from various diseases or from the use of certain drug therapies.

Tamoxifen has been shown in studies to be safe and effective in the prophylaxis and/or treatment of gynecomastia and breast pain associated with a number of drug therapies and other factors. Studies have been conducted to assess the feasibility of preparing tamoxifen citrate in a safe and effective topical formulation that can locally target ductal tissue. Additional research on tamoxifen citrate has shown that no metabolic degradation of tamoxifen occurs in the skin, which suggests suitability for topical delivery. 

Studies also show that Tamoxifen Citrate in various formulations can successfully pass through in vitro artificial and in vivo animal skin, and accumulate in subcutaneous tissues, absorb into the bloodstream, excrete in the urine and show significant antagonistic effects on estrogen-stimulated proliferation. 

This formulation uses a unique hydrophilic, occlusive vehicle with emollient and skin protective effects. The formulation is preservative-free with liposomal and penetration enhancing agents for optimal drug delivery.